Life Sciences mergers and acquisitions are typically based on perceived future value rather than objective financial parameters.
Published in In Vivo, September 2017
Author: Oded Ben-Joseph, Ph.D.
Life Sciences mergers and acquisitions are typically based on perceived future value rather than objective financial parameters, but the cognitive biases inherent in subjective assessments can derail deals. Executives need to take emotion out of the equation and rely on relevant data to craft successful transactions.
Mergers and acquisition transactions play a central role in the life sciences sector and are the catalyst for growth and transformation, driving innovation from the laboratory all the way to the patient. Life sciences companies often fall victim to recurring misconceptions that lead to unnecessary failure.
In this conversation, Stan Glazer, Managing Director at Outcome, shares insights from his extensive experience in the life sciences industry.
Read MoreOutcome Capital Life Science Market Pulse April 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?